Perigon Wealth Management LLC Buys 1,135 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Perigon Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.9% in the 4th quarter, HoldingsChannel reports. The firm owned 7,836 shares of the biopharmaceutical company’s stock after buying an additional 1,135 shares during the quarter. Perigon Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,048,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of REGN. Salomon & Ludwin LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $31,000. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $34,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $38,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of several research reports. Guggenheim increased their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Piper Sandler started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday. They issued an “overweight” rating and a $875.00 price target on the stock. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating for the company in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $804.70.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $761.85 on Friday. The stock has a 50-day simple moving average of $766.62 and a two-hundred day simple moving average of $712.96. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a market capitalization of $80.54 billion, a PE ratio of 18.33, a PEG ratio of 2.02 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $12.07 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EYLEA HD (aflibercept) received FDA approval with extended dosing intervals up to five months for wAMD and DME — this can raise lifetime patient value, reduce treatment burden, and boost Regeneron’s retina revenue and competitive positioning. EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
• Positive Sentiment: Regeneron struck a strategic collaboration with TriNetX to access ~300 million de‑identified EHR records, giving it broader phenotypic linkage to its genomic/proteomic datasets — this should accelerate target discovery, improve clinical-trial design, and strengthen AI-driven drug development over time. Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
• Positive Sentiment: Analyst commentary and Zacks/Yahoo pieces highlight Regeneron’s strong earnings‑surprise history and factors that point to another potential beat — supporting short‑term investor optimism ahead of upcoming results. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Regeneron told investors it expects to be excluded from the U.S. list facing proposed pharma tariffs — that reduces near‑term policy risk and potential margin pressure relative to peers. Regeneron says it expects to avoid new US pharma tariffs
• Neutral Sentiment: Piper Sandler has initiated coverage of Regeneron (details of the call/rating were not in the summary) — coverage can increase attention/liquidity but the impact depends on the firm’s stated rating and model. Piper Sandler Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Insider Activity

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock valued at $4,142,738 in the last quarter. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.